https://www.fiercebiotech.com/biotech/vaderis-lands-152m-squeeze-akt-inhibitor-through-phase-3-and-regulatory-approval
Vaderis' $152M to fund ph. 3 trial in rare blood vessel disorder
Aug 11, 2026 - The Basel-based biotech launched the late-stage study to evaluate engasertib in patients with hereditary hemorrhagic telangiectasia.
blood vessel disordervaderisfundtrialrare